



6 September 2011

Via (electronic mail)

To: Shareholders of Del Mar Pharmaceuticals

Re: Company update

Dear Shareholders and Friends of Del Mar Pharma:

On August 8, we reported to you that we had provided information requested by the US FDA related to our Investigational New Drug (IND) application to conduct human clinical trials with our lead drug candidate, VAL-083, in patients suffering from glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

I am pleased to report that the FDA has reviewed our submissions and has granted permission to begin clinical trials. Our team worked effectively to respond to the FDA queries and our achievement of this important milestone is a complement to everyone involved. The attached press-release will be issued tomorrow, September 6th.

As I mentioned in my previous update, we have agreed on terms of a \$3 million financing with a Toronto-based lead investor group to fund the trial and related corporate activities. I would be happy to discuss the offering with you or others with whom you feel our story may resonate.

On behalf of the DelMar Pharma team, thank you again for your support. I anticipate providing you with another update before the end of the year. In the meantime, please visit our website at www.delmarpharma.com for regular updates on our progress and activities.

Best personal Regards,

A handwritten signature in black ink, appearing to read "J. Bacha", with a long horizontal flourish extending to the right.

Jeffrey A. Bacha
President and CEO

<i>Corporate Headquarters</i>	<i>Clinical Operations</i>
Suite 116 – 887 Great Northern Way	3475 Edison Way, Suite R
Vancouver, British Columbia	Menlo Park, California 94025
Canada V5T 4T5	USA
www.delmarpharma.com	